Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Resectable NSCLC × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9357 Neoplasms 6503 Prostatic Neoplasms 4356 Colorectal Neoplasms 3922 Lung Neoplasms 3588 Carcinoma, Non-Small-Cell Lung 3541 Pancreatic Neoplasms 2442 Carcinoma, Hepatocellular 2378 Leukemia, Myeloid, Acute 2232 Multiple Myeloma 2099 Stomach Neoplasms 2076 Neoplasm Metastasis 1899 Head and Neck Neoplasms 1846 Ovarian Neoplasms 1756 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1724 Lymphoma 1720 Brain Neoplasms 1687 Rectal Neoplasms 1659 Melanoma 1641 Colonic Neoplasms 1619 Leukemia 1496 Uterine Cervical Neoplasms 1473 Recurrence 1466 Esophageal Neoplasms 1299 Glioblastoma 1285 Lymphoma, Non-Hodgkin 1199 Leukemia, Lymphocytic, Chronic, B-Cell 1117 Squamous Cell Carcinoma of Head and Neck 1092 Urinary Bladder Neoplasms 1066 Lymphoma, Follicular 1056

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡